Cover Image

Blue light cystoscopy with hexylaminolevulinate: Our 7 years experience

Vito Lacetera, Ubaldo Cantoro, Lorenzo Montesi, Daniele Cantoro, Bernardo Cervelli, Antonio Cicetti, Giuliana Gabrielloni, Domenico Milella, Michele Montesi, Roberto Morcellini, Gianni Parri, Emilio Recanatini, Valerio Beatrici
  • Vito Lacetera
    Azienda Ospedaliera Ospedali Riuniti Marche Nord, Pesaro-Fano, Italy
  • Lorenzo Montesi
    Azienda Ospedaliera Ospedali Riuniti Marche Nord, Pesaro-Fano, Italy
  • Daniele Cantoro
    Ospedale di Ascoli Piceno, Ascoli Piceno, Italy
  • Bernardo Cervelli
    Azienda Ospedaliera Ospedali Riuniti Marche Nord, Pesaro-Fano, Italy
  • Antonio Cicetti
    Azienda Ospedaliera Ospedali Riuniti Marche Nord, Pesaro-Fano, Italy
  • Giuliana Gabrielloni
    Azienda Ospedaliera Ospedali Riuniti Marche Nord, Pesaro-Fano, Italy
  • Domenico Milella
    Azienda Ospedaliera Ospedali Riuniti Marche Nord, Pesaro-Fano, Italy
  • Michele Montesi
    Azienda Ospedaliera Ospedali Riuniti Marche Nord, Pesaro-Fano, Italy
  • Roberto Morcellini
    Azienda Ospedaliera Ospedali Riuniti Marche Nord, Pesaro-Fano, Italy
  • Gianni Parri
    Azienda Ospedaliera Ospedali Riuniti Marche Nord, Pesaro-Fano, Italy
  • Emilio Recanatini
    Azienda Ospedaliera Ospedali Riuniti Marche Nord, Pesaro-Fano, Italy
  • Valerio Beatrici
    Azienda Ospedaliera Ospedali Riuniti Marche Nord, Pesaro-Fano, Italy

Abstract

Aim: The objective of the present study is to evaluate the diagnostic accuracy of hexylaminolevulinate (HAL) blue light cystoscopy compared with standard white light cystoscopy (WLC) in daily practice. Materials and methods: An observational, comparative, controlled (within patient) study was carried out at our Center. 61 consecutive patients with suspected or confirmed bladder cancer were recruited for the study from January 2008 until January 2015. Patients with suspected bladder cancer (positive cytology with negative WLC) or history of previous high-grade NMIBC or CIS were included in the study. Biopsies/resection of each positive lesion/suspicious areas were always taken after the bladder was inspected under WLC and BLC. Diagnoses of bladder tumor or CIS were considered as positive results, and the presence of normal urothelium in the biopsy specimen as negative result. Results: 61 BLC were performed. 15/61 (24.5%) with suspected initial diagnosis of NMIBC and 46/61 (75.5%) with a history of high-risk non-muscle invasive bladder cancer (NMIBC). We performed a total of 173 biopsies/TURBT of suspicious areas: 129 positive only to the BLC and 44 both positive to WLC and BLC. 84/173 biopsies/TURBT were positive for cancer. All 84 NMIBC were positive to the BLC, while 35/84 were positive to the WLC with a sensitivity of BLC and WLC respectively of 100% and 41.7%. Sensitivity of WLC for highgrade NMIBC and CIS was 34.1% and 39% respectively while sensitivity of BLC for high-grade NMIBC and CIS was 100%. The specificity of the WLC was 79.9% compared to 48.5% of the BLC. The positive predictive value of BLC and WLC were respectively 48% (95% CI: 0.447-0.523) and 79% (95% CI: 0.856-0.734). Conclusions: Our data confirm those reported in the literature: BLC increases the detection rate of NMIBC particularly in high risk patients (history of CIS or high grade). BLC is a powerful diagnostic tool in the diagnosis of bladder cancer if malignancy is suspected (positive urine cytology) and if conventional WLC is negative.

Keywords

Blue light cystoscopy; Hexaminolevulinate

Full Text:

PDF
Submitted: 2016-02-07 19:19:44
Published: 2017-03-31 00:00:00
Search for citations in Google Scholar
Related articles: Google Scholar
Abstract views:
154

Views:
PDF
120

Article Metrics

Metrics Loading ...

Metrics powered by PLOS ALM


Copyright (c) 2017 Vito Lacetera, Ubaldo Cantoro, Lorenzo Montesi, Daniele Cantoro, Bernardino Cervelli, Antonio Cicetti, Giuliana Gabrielloni, Domenico Milella, Michele Montesi, Roberto Morcellini, Gianni Parri, Emilio Recanatini, Valerio Beatrici

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
 
© PAGEPress 2008-2017     -     PAGEPress is a registered trademark property of PAGEPress srl, Italy.     -     VAT: IT02125780185